The vast power and resources of the pharmaceutical industry means that where patients and consumers suffer harm from faulty products or treatments, it can often be incredibly difficult for these individuals to seek legal recourse. However, the news of a group litigation order (GLO) being approved against a global pharmaceutical giant demonstrates the power of collective actions, especially those that are well-funded, in furthering access to justice.